At what hip fracture risk is it cost-effective to treat?
- 318 Downloads
Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK.
The aim of this study was to provide a Markov cohort model platform for a multinational estimation of thresholds at which intervention becomes cost-effective and to investigate and determine the main factors behind differences in these thresholds between countries.
Results and discussion
Intervention thresholds were estimated for Australia, Germany, Japan, Sweden, Spain, the UK and USA using a societal perspective. The model was populated with as much relevant country-specific data as possible. Intervention was assumed to be given for 5 years and to decrease the risk of all osteoporotic fractures by 35%. The societal willingness to pay (WTP) for a quality-adjusted life-year (QALY) gained was set to the gross domestic product (GDP) per capita multiplied by two. In the base case analysis, the 10-year hip fracture probability at which intervention became cost-effective varied across ages and countries. For women starting therapy at an age of 70 years, the IT varied from a hip fracture probability of 5.6% in Japan to 14.7% in Spain. The main factors explaining differences in the IT between countries were the WTP for a QALY gained, fracture-related costs and intervention costs.
The ITs presented in this paper are appropriate for use in treatment guidelines that consider health economic aspects, and they can be used in combination with fracture risk prediction algorithms to improve the selection of patients who are suitable for osteoporotic intervention.
KeywordsCost-effectiveness Hip fracture Intervention threshold Osteoporosis
- 14.Borgström F, Kanis JA, Johnell O, Jönsson B (2006) Are costs of fracture proportional to their morbidity?. Osteoporos Int ECCEO abstract 17[Suppl 2]:47Google Scholar
- 15.Borgström F, Kanis JA, Johnell O, Jönsson B (2006) Costing fractures for use in health economics modelling. Osteoporos Int ECCEO abstract 17[Suppl 2]: 97Google Scholar
- 16.ISPOR (2005) ISPOR pharmacoeconomic guidelines. http://www.ispor.org/PEguidelines/index.asp
- 20.Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9(22):1–160PubMedGoogle Scholar
- 23.Commission on Macroeconomics and Health (2001) Report on macroeconomics and health: investing in health for economic development. WHO, GenevaGoogle Scholar
- 24.Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361:717–725PubMedCrossRefGoogle Scholar
- 30.Euopean Commission – Employment and Social Affairs (1998) Report on Osteoporosis in the European Community - Action for Prevention. European Commission – Employment & Social Affairs, BrusselsGoogle Scholar
- 34.Government Actuary´s Department. Interim Life Tables. http://www.gad.gov.uk/policy_and_stats/life_tables.htm. Access date: 2004-10-15
- 35.Instituto Nacional del Estadistica (2002) Tablas de Mortalidad de la Población de España 1998–1999. MadridGoogle Scholar
- 36.Statistical Yearbook of Sweden (2004). Statistics Sweden, StockholmGoogle Scholar
- 37.Human Mortality Database. University of California, Berkeley (USA) and Max Planck Institute for Demographic Research (Germany)Google Scholar
- 41.Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2005) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 1–14Google Scholar
- 44.Hart WM, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. Rev Esp Enferm Metab Óseas 11:97–104Google Scholar
- 47.Kanis JA (2002) Epidemiology and costs of fractures in the UK: background document for male osteoporosis model. Personal communicationGoogle Scholar
- 49.OECD Health Data (2005)Google Scholar
- 56.Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
- 57.Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
- 60.World Bank (2003) World development indicators. The World Bank, Washington, D.C.Google Scholar
- 65.Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
- 66.Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
- 69.Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735PubMedCrossRefGoogle Scholar
- 70.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRefGoogle Scholar
- 72.Report on Government Services 2000 (2000) Canberra, AustraliaGoogle Scholar
- 73.Stadsledningskontorets redovisningsstab. Stockholms stads budgetavräkning. http://www.stockholm.se Access date: 2004–08–22
- 74.Netten A, Rees T, Harrison G; Unit Costs of health and Social Care (2002) Personal Social Services Research Unit, University of KentGoogle Scholar
- 75.MetLife Mature Market Institute (2003)Google Scholar